Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2012

Open Access 01-12-2012 | Oral presentation

Death receptor-induced apoptosis signalling - essential guardian against autoimmune disease

Authors: Andreas Strasser, Lorraine A O'Reilly, Philipp Jost, Thomas Kaufmann, Stephanie Grabow, Elizabeth Kruse, Lin Tai, Mark Smyth, Philippe Bouillet

Published in: Arthritis Research & Therapy | Special Issue 1/2012

Login to get access

Excerpt

The FasL/Fas system is critical for deletion of autoreactive and antigen-activated T and B cells. Accordingly, mutations in these proteins result in lymphadenopathy and autoimmunity in gld and lpr mutant mice, which lack functional FasL or Fas, respectively. Upon antigenic stimulation of T cells, FasL is sythesised, directed to and stored in secretory lysosomes followed by extrusion at the immunological synapse where it is rapidly downregulated by a metalloprotease, shedding the extracellular portion (sFasL) to prevent non-specific killing. It is unclear whether the pathology observed in gld mutant mice is due to the loss of the membrane-bound or the secreted form of FasL or both. …
Literature
1.
go back to reference Strasser A, Harris AW, Huang DCS, Krammer PH, Cory S: Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J. 1995, 14: 6136-6147.PubMedCentralPubMed Strasser A, Harris AW, Huang DCS, Krammer PH, Cory S: Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J. 1995, 14: 6136-6147.PubMedCentralPubMed
2.
go back to reference Newton K, Harris AW, Bath ML, Smith KGC, Strasser A: A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J. 1998, 17: 706-718. 10.1093/emboj/17.3.706.PubMedCentralCrossRefPubMed Newton K, Harris AW, Bath ML, Smith KGC, Strasser A: A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J. 1998, 17: 706-718. 10.1093/emboj/17.3.706.PubMedCentralCrossRefPubMed
3.
go back to reference Huang DCS, Hahne M, Schroeter M, Frei K, Fontana A, Villunger A, Newton K, Tschopp J, Strasser A: Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-xL. Proc Natl Acad Sci USA. 1999, 96: 14871-14876. 10.1073/pnas.96.26.14871.PubMedCentralCrossRefPubMed Huang DCS, Hahne M, Schroeter M, Frei K, Fontana A, Villunger A, Newton K, Tschopp J, Strasser A: Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-xL. Proc Natl Acad Sci USA. 1999, 96: 14871-14876. 10.1073/pnas.96.26.14871.PubMedCentralCrossRefPubMed
4.
go back to reference Kaufmann T, Tai L, Ekert PG, Huang DCS, Norris F, Lindemann RK, Johnstone RW, Dixit VM, Strasser A: The pro-apoptotic BH3-only protein Bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell cycle arrest. Cell. 2007, 129: 423-433. 10.1016/j.cell.2007.03.017.CrossRefPubMed Kaufmann T, Tai L, Ekert PG, Huang DCS, Norris F, Lindemann RK, Johnstone RW, Dixit VM, Strasser A: The pro-apoptotic BH3-only protein Bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell cycle arrest. Cell. 2007, 129: 423-433. 10.1016/j.cell.2007.03.017.CrossRefPubMed
5.
go back to reference Hughes PD, Belz GT, Fortner KA, Budd RC, Strasser A, Bouillet P: Fas and Bim cooperate in shutdown of chronic immune responses and prevention of autoimmunity. Immunity. 2008, 28: 197-205. 10.1016/j.immuni.2007.12.017.PubMedCentralCrossRefPubMed Hughes PD, Belz GT, Fortner KA, Budd RC, Strasser A, Bouillet P: Fas and Bim cooperate in shutdown of chronic immune responses and prevention of autoimmunity. Immunity. 2008, 28: 197-205. 10.1016/j.immuni.2007.12.017.PubMedCentralCrossRefPubMed
6.
go back to reference Kaufmann T, Jost P, Pellegrini M, Puthalakath H, Gugasyan R, Gerondakis S, Cretney E, Smyth M, Silke J, Hakem R, Bouillet P, Mak T, Dixit VM, Strasser A: Fatal hepatitis mediated by TNFa requires caspase-8 and involves the BH3-only proteins Bid and Bim. Immunity. 2009, 30: 56-66. 10.1016/j.immuni.2008.10.017.PubMedCentralCrossRefPubMed Kaufmann T, Jost P, Pellegrini M, Puthalakath H, Gugasyan R, Gerondakis S, Cretney E, Smyth M, Silke J, Hakem R, Bouillet P, Mak T, Dixit VM, Strasser A: Fatal hepatitis mediated by TNFa requires caspase-8 and involves the BH3-only proteins Bid and Bim. Immunity. 2009, 30: 56-66. 10.1016/j.immuni.2008.10.017.PubMedCentralCrossRefPubMed
7.
go back to reference Jost PJ, Grabow S, Gray D, McKenzie MD, Nachbur U, Huang DCS, Bouillet P, Thomas HE, Borner C, Silke J, Strasser A, Kaufmann T: XIAP acts as a switch between type I and type II Fas-induced apoptosis signalling. Nature. 2009, 460: 1035-1039. 10.1038/nature08229.PubMedCentralCrossRefPubMed Jost PJ, Grabow S, Gray D, McKenzie MD, Nachbur U, Huang DCS, Bouillet P, Thomas HE, Borner C, Silke J, Strasser A, Kaufmann T: XIAP acts as a switch between type I and type II Fas-induced apoptosis signalling. Nature. 2009, 460: 1035-1039. 10.1038/nature08229.PubMedCentralCrossRefPubMed
8.
go back to reference O'Reilly LA, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD, Haynes NM, Tarlinton DM, Zhang J-G, Belz GT, Smyth MJ, Bouillet P, Robb L, Strasser A: Membrane-bound but not secreted Fas ligand is essential for Fas-induced apoptosis and prevention of autoimmunity and cancer. Nature. 2009, 461: 659-663. 10.1038/nature08402.CrossRef O'Reilly LA, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD, Haynes NM, Tarlinton DM, Zhang J-G, Belz GT, Smyth MJ, Bouillet P, Robb L, Strasser A: Membrane-bound but not secreted Fas ligand is essential for Fas-induced apoptosis and prevention of autoimmunity and cancer. Nature. 2009, 461: 659-663. 10.1038/nature08402.CrossRef
9.
Metadata
Title
Death receptor-induced apoptosis signalling - essential guardian against autoimmune disease
Authors
Andreas Strasser
Lorraine A O'Reilly
Philipp Jost
Thomas Kaufmann
Stephanie Grabow
Elizabeth Kruse
Lin Tai
Mark Smyth
Philippe Bouillet
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 1/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3563

Other articles of this Special Issue 1/2012

Arthritis Research & Therapy 1/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.